|
21 May 2019 |
Evotec jump-starts biologics with acquisition of Just Biotherapeutics
|
|
21 May 2019 |
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
|
|
21 May 2019 |
CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary
|
|
21 May 2019 |
Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse
|
|
18 May 2019 |
Ligand Licenses VER250840 to Cumulus Oncology
|
|
16 May 2019 |
Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products
|
|
16 May 2019 |
HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia
|
|
16 May 2019 |
ASC Therapeutics Licenses Critical Technologies for Hemophilia A Gene Therapy from Expression Therapeutics
|
|
16 May 2019 |
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases
|
|
16 May 2019 |
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
|
|
15 May 2019 |
Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
|
|
15 May 2019 |
Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases
|
|
15 May 2019 |
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
|
|
14 May 2019 |
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
|
|
12 May 2019 |
TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) Increases Penetration and Antitumor Activity of Anti-CEA CAR-T in Mouse Model of Liver Metastases
|
|
10 May 2019 |
Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets
|
|
10 May 2019 |
Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
|
|
09 May 2019 |
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
|
|
08 May 2019 |
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
|
|
08 May 2019 |
Curadev Announces Licensing Agreement With Takeda for Novel STING Agonist
|
|
08 May 2019 |
Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease
|
|
08 May 2019 |
BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio
|
|
08 May 2019 |
Pfizer Acquires Clinical-Stage Biotech Therachon
|
|
03 May 2019 |
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
|
|
02 May 2019 |
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies
|
